초록 ▼

The invention is a freeze tolerant fuel cell power plant that includes at least one fuel cell; a coolant loop having a coolant circulating device that directs a water coolant through a water transport plate within the fuel cell; and a water displacement system having a freeze tolerant accumulator th

The invention is a freeze tolerant fuel cell power plant that includes at least one fuel cell; a coolant loop having a coolant circulating device that directs a water coolant through a water transport plate within the fuel cell; and a water displacement system having a freeze tolerant accumulator that contains a water immiscible fluid and water coolant. The water displacement system also includes a water immiscible fluid pump, heater and displacement valves for directing the water immiscible fluid to flow from the accumulator into the coolant loop; for directing the water coolant in the coolant loop to flow into the accumulator; and, for directing heated water immiscible fluid to flow from the accumulator into the coolant loop and back into the accumulator.

대표청구항 ▼

The invention is a freeze tolerant fuel cell power plant that includes at least one fuel cell; a coolant loop having a coolant circulating device that directs a water coolant through a water transport plate within the fuel cell; and a water displacement system having a freeze tolerant accumulator th

The invention is a freeze tolerant fuel cell power plant that includes at least one fuel cell; a coolant loop having a coolant circulating device that directs a water coolant through a water transport plate within the fuel cell; and a water displacement system having a freeze tolerant accumulator that contains a water immiscible fluid and water coolant. The water displacement system also includes a water immiscible fluid pump, heater and displacement valves for directing the water immiscible fluid to flow from the accumulator into the coolant loop; for directing the water coolant in the coolant loop to flow into the accumulator; and, for directing heated water immiscible fluid to flow from the accumulator into the coolant loop and back into the accumulator. ntial for Hyperkalemia, Mueller, et al., pp. 310-312. Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, No. 10, Oct. 1997, Monounsaturated and Polyunsaturated n-6 Fatty Acid-Enriched Diets Modify LDL Oxidation and Decrease Human Coronary Smooth Muscle Cell DNA Synthesis, Mata, et al. Antioxidant activity of polyphenolics in diets Rate constants of Reactions of Chlorogenic acid and Caffeic acid with reactive species of oxygen and nitrogen, Kono, et al., Nov. 1996, vol. 1335, pp, 335-342. Association of Serum Vitamin Levels, LDL Susceptibility to Oxidation, and Autoantibodies against MDA-LDL with Carotid Atherosclerosis, Iribarren, et al., Aug. 21, 1996, vol. 17, No. 6, Jun. 1997, 73-7120(SP) ISSN 1079-5642, pp. 1171-1177. Iakovieva, et al., 61(3) Eksp.Klin, FarmaKol. 32-4, 1998. Archives of Internal Medicine, Flavonoid intake and Long-Term Risk of Coronary Heart Disease and Cancer in the Seven Countries Study, Hertog, et al., Feb. 27, 1995, vol. 155, pp. 381-386. The American Journal of Clinical Nutrition, May 1997, vol. 65, No. 5, Antioxidant flavonols and ischemic heart disease in a Welsh population of men: The Caerphilly Study 1-3, Hertog, et al., 65:1489-94. Atherosclerosis, Official Journal of the European Atherosclerosis Society, Affiliated with the International Atherosclerosis Society, vol. 137, Apr. 1998, ISSN: 0021-9150, Suppl S1-S124, Brugge, LDL Oxidation: Therapeutic perspectives, Heller, et al. Free Radicals in Biology & Medicine, Kelvin J. A. Davies, Ph.D, vol. 2, No. 3, 1986, Intracellular Proteolytic Systems may Function as Secondary Antioxidant Defenses: An Hypothesis, HSC-PSC 614-616, pp. 155-173. Planta Medica, vol. 57, Jun. 1991, pp. 203-298, Choi, et al., Improvement of Hyperglycemia in Streptozotocin-Diabetic Rats by a Methanolic Extract of Prunus davidiana Stems and its Main Component, Prunin. E 21 804 F. Journal of Natural Products, Jan.-Feb., 1991. vol. 54, No. 1, Coden JNPRDF 54 (1) 1-327, ISSN: 0163-3864, Antihyperlipidemic Effect of Flavonoids from Prunus Davidiana, Jae Sue Chio, Pusan 608-023, pp. 218-224. Polyphenolic Flavonoids Inhibit Macrophage-Mediated Oxidation of LDL and Attenuate Atherogenesis, Atherosclerosis 137, 1998, S45-S50, Aviram, et al. Clinical Nutrition, May 2000, vol. 71, No. 5, ISSN 0002-9165, Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: Studies in humans and in Atherosclerotic Apolipoprotein E-Deficient Mice 1,2. Aviram, et al., Am J Clin Nutr 2000; 71:1062-76. World Review of Nutrition and Dietetics, vol. 24, 1976, Wld Rev. Nutr. Diet., pp. 117-191, The Flavonoids. A Class of Semi-Essential Food Components: Their Role in Human Nutrition, Joachim Kuhnau. t 25 mg to about 75 mg. 12. The method of claim 1, wherein said apple extract is about 25 mg to about 75 mg. 13. The method of claim 1, wherein said enzyme mixture is about 15 mg to about 75 mg. 14. The method of claim 1, wherein said enzyme mixture comprises one or more enzymes selected from the group consisting of amylase, cellulase, hemicellulase, and protease. 15. The method of claim 1, wherein said composition comprises: 100 mg of Morinda citrifolia extract, 100 mg of red wine extract, 75 mg of prune extract, 50 mg of blueberry extract, 50 mg of pomegranate extract, 50 mg of apple extract, and 30 mg of an enzyme mixture. 16. The method of claim 15, wherein said enzyme mixture comprises one or more enzymes selected from the group consisting of amylase, cellulase, hemicellulase, and protease. 17. The method of claim 1, wherein said composition is delivered in a pharmaceutically acceptable carrier. 18. The method of claim 1, wherein said composition is administered 2 to 3 times daily. 19. The method of claim 18, wherein said administration is selected from the group consisting of peroral, liposornal, inhalation, sublingual, rectal, oral and dermal. 20. The method of claim 18, wherein said composition is administered orally. 21. The method of claim 1, wherein said composition is provided in a form selected from the group consisting of a gel cap and an emulsion. 22. The method of claim 1, wherein said composition is in solid form selected from the group consisting of a tablet and a capsule. 23. The method of claim 1, wherein said mammal is a human. 24. The method of claim 23, wherein said normalizing of the triglyceride level of a mammal comprises reducing the triglyceride level of said mammal. 25. The method of claim 24, wherein said reducing of the triglyceride level of said mammal reduces blood triglyceride level in mammals having a triglyceride level of at least 200 mg/dL (2.26 mmol/L).